---
title: "JIUDIAN PHARMACEUTICAL: PDX-04 has been approved to conduct clinical trials for pain relief in acute gout attacks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241817384.md"
description: "JIUDIAN PHARMACEUTICAL recently received approval from the National Medical Products Administration to conduct clinical trials for PDX-04 for the treatment of acute gout attacks. There are currently no clinical trials or market records for this drug domestically or internationally"
datetime: "2025-05-26T09:06:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241817384.md)
  - [en](https://longbridge.com/en/news/241817384.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241817384.md)
generator: "portal-rs"
---

# JIUDIAN PHARMACEUTICAL: PDX-04 has been approved to conduct clinical trials for pain relief in acute gout attacks

According to the Zhitong Finance APP, JIUDIAN PHARMACEUTICAL (300705.SZ) announced that it recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After completing the relevant preparatory work, it will carry out clinical trial research involving the drug: "PDX-04". PDX-04 is a drug used for the treatment of acute gout attacks. Currently, there are no products in this category undergoing clinical trials domestically or internationally, and there are no approved products or related sales data

### Related Stocks

- [300705.CN](https://longbridge.com/en/quote/300705.CN.md)

## Related News & Research

- [17:25 ETHard Rock Hotel Malta Celebrates Star-Studded Grand Opening in St. George's Bay](https://longbridge.com/en/news/297833025.md)
- [Anker’s new printer works directly on fabrics](https://longbridge.com/en/news/297876578.md)
- [US FDA is working with manufacturers to boost estradiol patch supply amid access concerns](https://longbridge.com/en/news/297917790.md)
- [16:48 ETBeverly Hills MD Dermal Repair Complex Wins Beauty Product of the Year](https://longbridge.com/en/news/297957835.md)
- [Palvella completes rolling FDA NDA submission for QTORIN rapamycin in microcystic lymphatic malformations](https://longbridge.com/en/news/297509688.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**